Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AMGN Amgen	$360.45 -0.8%	$345.09	$269.77 ▼ $391.29	$196.12B	0.41	2.60 million shs	2.06 million shs
CPRX Catalyst Pharmaceuticals	$31.48 +0.0%	$31.31	$19.05 ▼ $32.56	$3.85B	0.74	1.90 million shs	3.38 million shs
GILD Gilead Sciences	$131.40 +1.2%	$129.79	$107.75 ▼ $157.29	$161.19B	0.32	7.92 million shs	5.11 million shs
IMCR Immunocore	$32.49 +1.7%	$29.76	$27.56 ▼ $40.71	$1.63B	0.73	619,023 shs	896,475 shs
MDY SPDR S&P MidCap 400 ETF Trust	$685.98 -0.6%	$682.11	$559.89 ▼ $704.45	$27.08B	1	965,855 shs	566,791 shs
NBIX Neurocrine Biosciences	$174.10 -1.7%	$161.69	$122.14 ▼ $181.18	$17.81B	0.39	1.10 million shs	1.57 million shs
REGN Regeneron Pharmaceuticals	$663.09 -0.2%	$644.42	$541.00 ▼ $821.11	$70.25B	0.24	939,951 shs	604,985 shs
VRTX Vertex Pharmaceuticals	$480.25 -1.1%	$458.18	$362.50 ▼ $533.67	$123.19B	0.29	1.96 million shs	1.15 million shs

10 Stocks Powering The Next AI Boom

The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation.

Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AMGN Amgen	-0.81%	-1.63%	+1.48%	+2.71%	+22.07%
CPRX Catalyst Pharmaceuticals	+0.03%	-0.06%	+0.38%	+20.20%	+44.34%
GILD Gilead Sciences	+1.21%	+1.38%	+4.63%	-6.44%	+19.85%
IMCR Immunocore	+1.69%	+1.72%	+12.19%	+2.52%	-7.22%
MDY SPDR S&P MidCap 400 ETF Trust	-0.56%	-1.53%	-1.12%	+4.99%	+18.43%
NBIX Neurocrine Biosciences	-1.70%	0.00%	+8.98%	+33.09%	+30.45%
REGN Regeneron Pharmaceuticals	-0.22%	+2.04%	+8.32%	-12.23%	+16.79%
VRTX Vertex Pharmaceuticals	-1.06%	-9.32%	+7.94%	+8.10%	+2.43%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AMGN Amgen	$360.45 -0.8%	$345.09	$269.77 ▼ $391.29	$196.12B	0.41	2.60 million shs	2.06 million shs
CPRX Catalyst Pharmaceuticals	$31.48 +0.0%	$31.31	$19.05 ▼ $32.56	$3.85B	0.74	1.90 million shs	3.38 million shs
GILD Gilead Sciences	$131.40 +1.2%	$129.79	$107.75 ▼ $157.29	$161.19B	0.32	7.92 million shs	5.11 million shs
IMCR Immunocore	$32.49 +1.7%	$29.76	$27.56 ▼ $40.71	$1.63B	0.73	619,023 shs	896,475 shs
MDY SPDR S&P MidCap 400 ETF Trust	$685.98 -0.6%	$682.11	$559.89 ▼ $704.45	$27.08B	1	965,855 shs	566,791 shs
NBIX Neurocrine Biosciences	$174.10 -1.7%	$161.69	$122.14 ▼ $181.18	$17.81B	0.39	1.10 million shs	1.57 million shs
REGN Regeneron Pharmaceuticals	$663.09 -0.2%	$644.42	$541.00 ▼ $821.11	$70.25B	0.24	939,951 shs	604,985 shs
VRTX Vertex Pharmaceuticals	$480.25 -1.1%	$458.18	$362.50 ▼ $533.67	$123.19B	0.29	1.96 million shs	1.15 million shs

10 Stocks Powering The Next AI Boom

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AMGN Amgen	-0.81%	-1.63%	+1.48%	+2.71%	+22.07%
CPRX Catalyst Pharmaceuticals	+0.03%	-0.06%	+0.38%	+20.20%	+44.34%
GILD Gilead Sciences	+1.21%	+1.38%	+4.63%	-6.44%	+19.85%
IMCR Immunocore	+1.69%	+1.72%	+12.19%	+2.52%	-7.22%
MDY SPDR S&P MidCap 400 ETF Trust	-0.56%	-1.53%	-1.12%	+4.99%	+18.43%
NBIX Neurocrine Biosciences	-1.70%	0.00%	+8.98%	+33.09%	+30.45%
REGN Regeneron Pharmaceuticals	-0.22%	+2.04%	+8.32%	-12.23%	+16.79%
VRTX Vertex Pharmaceuticals	-1.06%	-9.32%	+7.94%	+8.10%	+2.43%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AMGN Amgen	2.43	Hold	$356.62	-1.06% Downside
CPRX Catalyst Pharmaceuticals	2.56	Moderate Buy	$32.00	1.65% Upside
GILD Gilead Sciences	2.90	Moderate Buy	$159.04	21.03% Upside
IMCR Immunocore	2.40	Hold	$56.71	74.56% Upside
MDY SPDR S&P MidCap 400 ETF Trust	2.78	Moderate Buy	$685.98	N/A
NBIX Neurocrine Biosciences	2.96	Moderate Buy	$191.67	10.09% Upside
REGN Regeneron Pharmaceuticals	2.70	Moderate Buy	$787.67	18.79% Upside
VRTX Vertex Pharmaceuticals	2.84	Moderate Buy	$559.61	16.52% Upside

Current Analyst Ratings Breakdown

Latest NBIX, MDY, CPRX, IMCR, AMGN, VRTX, REGN, and GILD Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/13/2026	VRTX Vertex Pharmaceuticals	UBS Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$545.00 ➝ $585.00
7/13/2026	AMGN Amgen	UBS Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$400.00 ➝ $420.00
7/13/2026	VRTX Vertex Pharmaceuticals	Truist Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$542.00 ➝ $560.00
7/13/2026	IMCR Immunocore	Cantor Fitzgerald Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Overweight
7/13/2026	AMGN Amgen	Guggenheim Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Neutral	$340.00 ➝ $343.00
7/13/2026	NBIX Neurocrine Biosciences	Truist Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$155.00 ➝ $200.00
7/13/2026	NBIX Neurocrine Biosciences	BMO Capital Markets Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Market Perform	$144.00 ➝ $170.00
7/10/2026	NBIX Neurocrine Biosciences	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Buy (B) ➝ Buy (B-)
7/9/2026	REGN Regeneron Pharmaceuticals	Piper Sandler Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Overweight	$855.00 ➝ $854.00
7/8/2026	AMGN Amgen	Morgan Stanley Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Equal Weight	$340.00 ➝ $333.00
7/8/2026	GILD Gilead Sciences	Morgan Stanley Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Overweight	$168.00 ➝ $166.00

(Data available from 7/14/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AMGN Amgen	$36.75B	5.29	$33.53 per share	10.75	$16.08 per share	22.42
CPRX Catalyst Pharmaceuticals	$588.99M	6.54	$2.92 per share	10.77	$7.76 per share	4.06
GILD Gilead Sciences	$29.44B	5.54	$10.60 per share	12.40	$18.23 per share	7.21
IMCR Immunocore	$400.02M	4.13	N/A	N/A	$7.52 per share	4.32
MDY SPDR S&P MidCap 400 ETF Trust	N/A	N/A	N/A	N/A	N/A	N/A
NBIX Neurocrine Biosciences	$2.86B	6.12	$4.93 per share	35.33	$32.63 per share	5.34
REGN Regeneron Pharmaceuticals	$14.34B	4.89	$41.89 per share	15.83	$295.66 per share	2.24
VRTX Vertex Pharmaceuticals	$12.00B	10.16	$17.39 per share	27.62	$73.57 per share	6.53

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AMGN Amgen	$7.71B	$14.37	25.08	15.26	3.59	20.96%	137.41%	13.28%	8/4/2026 (Estimated)
CPRX Catalyst Pharmaceuticals	$214.33M	$1.74	18.09	10.22	0.96	37.08%	35.76%	31.31%	8/5/2026 (Estimated)
GILD Gilead Sciences	$8.51B	$7.34	17.90	13.53	N/A	30.99%	48.19%	18.28%	8/6/2026 (Estimated)
IMCR Immunocore	-$35.51M	-$0.55	N/A	37.34	N/A	-6.68%	-7.07%	-2.55%	8/6/2026 (Estimated)
MDY SPDR S&P MidCap 400 ETF Trust	N/A	N/A	18.98	N/A	N/A	N/A	N/A	N/A	N/A
NBIX Neurocrine Biosciences	$478.60M	$6.49	26.83	17.50	0.71	21.55%	19.79%	13.82%	7/30/2026 (Estimated)
REGN Regeneron Pharmaceuticals	$4.50B	$41.04	16.16	15.92	1.47	29.65%	13.16%	10.17%	7/30/2026 (Estimated)
VRTX Vertex Pharmaceuticals	$3.95B	$16.86	28.48	25.32	2.07	35.51%	23.86%	17.13%	8/3/2026 (Estimated)

Latest NBIX, MDY, CPRX, IMCR, AMGN, VRTX, REGN, and GILD Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/6/2026	Q2 2026	GILD Gilead Sciences	-$7.13	N/A	N/A	N/A	$7.40 billion	N/A
8/6/2026	Q2 2026	IMCR Immunocore	-$0.01	N/A	N/A	N/A	$146.89 million	N/A
8/5/2026	Q2 2026	CPRX Catalyst Pharmaceuticals	$0.48	N/A	N/A	N/A	$155.79 million	N/A
8/4/2026	Q2 2026	AMGN Amgen	$5.56	N/A	N/A	N/A	$9.43 billion	N/A
8/3/2026	Q2 2026	VRTX Vertex Pharmaceuticals	$4.72	N/A	N/A	N/A	$3.22 billion	N/A
7/30/2026	Q2 2026	NBIX Neurocrine Biosciences	$2.19	N/A	N/A	N/A	$885.16 million	N/A
7/30/2026	Q2 2026	REGN Regeneron Pharmaceuticals	$10.40	N/A	N/A	N/A	$3.81 billion	N/A
5/7/2026	Q1 2026	GILD Gilead Sciences	$1.91	$2.03	+$0.12	$1.61	$6.91 billion	$6.96 billion
5/6/2026	Q1 2026	IMCR Immunocore	-$0.26	$0.25	+$0.51	$0.25	$145.20 million	$106.68 million
5/4/2026	Q1 2026	VRTX Vertex Pharmaceuticals	$4.24	$4.47	+$0.23	$4.02	$2.99 billion	$2.99 billion
4/30/2026	Q1 2026	AMGN Amgen	$4.77	$5.15	+$0.38	$3.34	$8.58 billion	$8.62 billion

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
AMGN Amgen	$10.08	2.80%	+8.27%	70.15%	14 Years
CPRX Catalyst Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
GILD Gilead Sciences	$3.28	2.50%	+3.04%	44.69%	10 Years
IMCR Immunocore	N/A	N/A	N/A	N/A	N/A
MDY SPDR S&P MidCap 400 ETF Trust	$7.02	1.02%	N/A	N/A	N/A
NBIX Neurocrine Biosciences	N/A	N/A	N/A	N/A	N/A
REGN Regeneron Pharmaceuticals	$3.76	0.57%	N/A	9.16%	N/A
VRTX Vertex Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Latest NBIX, MDY, CPRX, IMCR, AMGN, VRTX, REGN, and GILD Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
4/29/2026	GILD Gilead Sciences	quarterly	$0.82	2.64%	6/15/2026	6/15/2026	6/29/2026
4/29/2026	REGN Regeneron Pharmaceuticals	quarterly	$0.94	0.58%	5/20/2026	5/20/2026	6/4/2026

(Data available from 1/1/2013 forward)

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AMGN Amgen	5.65	1.26	1.01
CPRX Catalyst Pharmaceuticals	N/A	7.10	6.84
GILD Gilead Sciences	0.89	1.97	1.77
IMCR Immunocore	1.00	4.18	4.15
MDY SPDR S&P MidCap 400 ETF Trust	N/A	N/A	N/A
NBIX Neurocrine Biosciences	N/A	2.93	2.85
REGN Regeneron Pharmaceuticals	0.06	3.57	2.96
VRTX Vertex Pharmaceuticals	N/A	3.02	2.57

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AMGN Amgen	76.50%
CPRX Catalyst Pharmaceuticals	79.22%
GILD Gilead Sciences	83.67%
IMCR Immunocore	84.50%
MDY SPDR S&P MidCap 400 ETF Trust	N/A
NBIX Neurocrine Biosciences	92.59%
REGN Regeneron Pharmaceuticals	83.31%
VRTX Vertex Pharmaceuticals	90.96%

Insider Ownership

Company	Insider Ownership
AMGN Amgen	0.85%
CPRX Catalyst Pharmaceuticals	10.40%
GILD Gilead Sciences	0.30%
IMCR Immunocore	10.10%
MDY SPDR S&P MidCap 400 ETF Trust	N/A
NBIX Neurocrine Biosciences	4.60%
REGN Regeneron Pharmaceuticals	6.97%
VRTX Vertex Pharmaceuticals	0.20%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AMGN Amgen	31,500	539.71 million	535.12 million	Optionable
CPRX Catalyst Pharmaceuticals	80	122.42 million	109.69 million	Optionable
GILD Gilead Sciences	17,000	1.24 billion	1.24 billion	Optionable
IMCR Immunocore	320	50.87 million	45.73 million	Optionable
MDY SPDR S&P MidCap 400 ETF Trust	N/A	39.47 million	N/A	Not Optionable
NBIX Neurocrine Biosciences	2,000	100.55 million	95.93 million	Optionable
REGN Regeneron Pharmaceuticals	15,410	105.72 million	98.35 million	Optionable
VRTX Vertex Pharmaceuticals	6,400	253.80 million	253.30 million	Optionable

NBIX, MDY, CPRX, IMCR, AMGN, VRTX, REGN, and GILD Headlines

Recent News About These Companies

Vertex Pharmaceuticals (VRTX) Declines More Than Market: Some Information for Investors

1 hour ago | finance.yahoo.com

Vertex Pharmaceuticals (VRTX) Declines More Than Market: Some Information for Investors

July 13 at 7:01 PM | zacks.com

Does Vertex's Acquisition of Crinetics Pharmaceuticals Make the Stock a No-Brainer Buy?

July 13 at 6:41 PM | fool.com

Vortex Energy Corp. Announces Closing of LIFE Offering

July 13 at 6:41 PM | finance.yahoo.com

Does Vertex's Acquisition of Crinetics Pharmaceuticals Make the Stock a No-Brainer Buy?

July 13 at 2:50 PM | fool.com

What to Expect From Vertex Pharmaceuticals' Next Quarterly Earnings Report

July 13 at 10:11 AM | barchart.com

Vertex Pharmaceuticals: Buy Rating Reaffirmed as Analyst Lifts Price Target from $598 to $600 on Robust CF Growth and Emerging Nephrology/Endocrinology Upside

July 13 at 6:11 AM | tipranks.com

LGT Fund Management Co Ltd. Takes $2.26 Million Position in Vertex Pharmaceuticals Incorporated $VRTX

July 13 at 5:36 AM | marketbeat.com

Fifth Third Bancorp Acquires 66,341 Shares of Vertex Pharmaceuticals Incorporated $VRTX

July 13 at 3:43 AM | marketbeat.com

AMF Tjanstepension AB Has $139.73 Million Holdings in Vertex Pharmaceuticals Incorporated $VRTX

July 13 at 3:12 AM | marketbeat.com

Citizens Financial Group Inc. RI Purchases 6,421 Shares of Vertex Pharmaceuticals Incorporated $VRTX

July 12 at 11:19 AM | marketbeat.com

Vertex (VRTX) Wins FDA Expansion For CASGEVY And Advances ALYFTREK In Canada

July 11 at 11:41 PM | finance.yahoo.com

Vertex Pharmaceuticals Bets $10 Billion on Crinetics to Build Endocrinology Powerhouse

July 11 at 5:01 PM | marketbeat.com

Manning & Napier Advisors LLC Has $98.50 Million Stock Position in Vertex Pharmaceuticals Incorporated $VRTX

July 11 at 10:39 AM | marketbeat.com

Candriam S.C.A. Purchases 3,623 Shares of Vertex Pharmaceuticals Incorporated $VRTX

July 11 at 9:19 AM | marketbeat.com

Why This Pharmaceutical Stock Jumped Close to 100% This Week

July 10, 2026 | fool.com

Is This Biotech Stock a Buy Near Its 52-Week High?

July 10, 2026 | fool.com

If You Invested $1000 in Vertex Pharmaceuticals a Decade Ago, This is How Much It'd Be Worth Now

July 10, 2026 | finance.yahoo.com

The Long Climb Back For Ionis Stock

July 10, 2026 | trefis.comT

Beyond The Breakout Drug: Is BridgeBio Pharma Stock A Buy On Its Next Act?

July 10, 2026 | trefis.comT

Vertex Pharmaceuticals Just Made a $10 Billion Move. Is the Stock a Buy?

July 10, 2026 | fool.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

NBIX, MDY, CPRX, IMCR, AMGN, VRTX, REGN, and GILD Company Descriptions

Amgen NASDAQ:AMGN

$360.45 -2.94 (-0.81%)

Closing price 07/13/2026 04:00 PM Eastern

Extended Trading

$362.19 +1.74 (+0.48%)

As of 07/13/2026 07:59 PM Eastern

Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout. It also markets other products, including Neulasta, MVASI, AMJEVITA/AMGEVITA, TEZSPIRE, Parsabiv, Aimovig, LUMAKRAS/LUMYKRAS, EPOGEN, KANJINTI, TAVNEOS, RAVICTI, UPLIZNA and PROCYSBI. The company serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. The company has collaboration agreements with AstraZeneca plc for the development and commercialization of TEZSPIRE; Novartis Pharma AG to develop and commercialize Aimovig; UCB for the development and commercialization of EVENITY; Kyowa Kirin Co., Ltd. for rocatinlimab development and commercialization; and BeiGene, Ltd. for oncology products expansion and development. Amgen Inc. was incorporated in 1980 and is headquartered in Thousand Oaks, California.

Catalyst Pharmaceuticals NASDAQ:CPRX

$31.48 +0.01 (+0.03%)

Closing price 07/13/2026 04:00 PM Eastern

Extended Trading

$31.48 +0.00 (+0.02%)

As of 07/13/2026 07:34 PM Eastern

Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients. The company develops Firdapse for the treatment of MuSK antibody positive myasthenia gravis and spinal muscular atrophy type. It has license agreements with BioMarin Pharmaceutical Inc.; and collaboration and license agreement with Endo Ventures Limited for the development and commercialization of generic Sabril tablets. The company was founded in 2002 and is based in Coral Gables, Florida.

Gilead Sciences NASDAQ:GILD

$131.40 +1.57 (+1.21%)

Closing price 07/13/2026 04:00 PM Eastern

Extended Trading

$131.06 -0.34 (-0.26%)

As of 07/13/2026 07:59 PM Eastern

Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis. It also offers Yescarta, Tecartus, and Trodelvy products for the treatment of oncology; Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. The company has collaboration agreements with Arcus Biosciences, Inc.; Merck Sharp & Dohme Corp.; Pionyr Immunotherapeutics Inc.; Tizona Therapeutics, Inc.; Galapagos NV; Janssen Sciences Ireland Unlimited Company; Japan Tobacco, Inc.; Dragonfly Therapeutics, Inc.; Arcellx, Inc.; Everest Medicines; Merck & Co, Inc.; Tentarix Biotherapeutics Inc.; and Assembly Biosciences, Inc. It also has research collaboration, option, and license agreement with Merus N.V. for the discovery of novel dual tumor-associated antigens (TAA) targeting trispecific antibodies. The company was incorporated in 1987 and is headquartered in Foster City, California.

Immunocore NASDAQ:IMCR

$32.49 +0.54 (+1.69%)

Closing price 07/13/2026 04:00 PM Eastern

Extended Trading

$32.46 -0.04 (-0.11%)

As of 07/13/2026 06:09 PM Eastern

Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. It also develops other programs for oncology, including tebentafusp that is in Phase 2/3 clinical trial to treat advanced cutaneous melanoma. In addition, the company's product pipeline comprises IMC-F106C, which is in a Phase 3 clinical trial to treat first line advanced cutaneous melanoma; and in a Phase 1/2 clinical trial in multiple tumor types, such as platinum resistant ovarian, non-small cell lung, and endometrial carcinoma. Further, it develops IMC-R117C, which is in phase 1 clinical trial to treat colorectal and gastrointestinal cancers; IMC-M113V, which is in phase 1 clinical trial to treat human immunosuppression virus; IMC-I109V, which is in a Phase I clinical trial in patients with chronic hepatitis B virus; IMC-T119C, which is in preclinical trial for multiple solid tumor cancers; IMC-P115C, which is in preclinical trial to treat multiple solid tumor cancers; and IMC-S118AI to treat type 1 diabetes and is in preclinical trial. Immunocore Holdings plc was founded in 1999 and is headquartered in Abingdon, the United Kingdom.

SPDR S&P MidCap 400 ETF Trust NYSEARCA:MDY

$685.98 -3.84 (-0.56%)

Closing price 07/13/2026 04:10 PM Eastern

Extended Trading

$685.25 -0.73 (-0.11%)

As of 07/13/2026 08:00 PM Eastern

SPDR S&P MidCap 400 ETF is an exchange traded fund. SPDR MidCap 400 Trust focuses to correspond to the price and yield performance of the S&P MidCap 400 Index. The S&P MidCap 400 covers over 7% of the United States equities market, and is part of a series of S&P the United States indices. The index also includes companies, which should have four consecutive quarters of positive as-reported earnings, excluding discontinued operations and extraordinary items. Its investment sectors include financials, industrials, information technology, consumer discretionary, healthcare and materials. Bank of New York acts as an investment manager.

Neurocrine Biosciences NASDAQ:NBIX

$174.10 -3.01 (-1.70%)

Closing price 07/13/2026 04:00 PM Eastern

Extended Trading

$174.09 -0.01 (-0.01%)

As of 07/13/2026 07:40 PM Eastern

Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids. Its product candidates in clinical development include valbenazine to treat dyskinetic cerebral palsy in pediatrics and adults; NBI-921352 to treat developmental and epileptic encephalopathy syndrome in pediatrics and adults; NBI-827104 to treat epileptic encephalopathy with continuous spike-and-wave during sleep; NBI-1076986 to treat movement disorders; crinecerfront to treat congenital adrenal hyperplasia in adults and children; EFMODY to treat congenital adrenal hyperplasia and adrenal insufficiency in adults; valbenazine for the adjunctive treatment of schizophrenia; NBI-1065845 for the treatment of inadequate response to treatment in major depressive disorder; luvadaxistat to treat cognitive impairment related to schizophrenia; NBI-1117568 for the treatment of schizophrenia; NBI-1070770 to treat major depressive disorder; NBI-1117570 for the treatment of symptoms of psychosis and cognition in neurological and neuropsychiatric conditions; and NBI-1117569, NBI-1117567, and NBI-1065890 to treat CNS indications. The company also has license and collaboration agreements with Heptares Therapeutics Limited; Takeda Pharmaceutical Company Limited; Idorsia Pharmaceuticals Ltd; Xenon Pharmaceuticals Inc.; Voyager Therapeutics, Inc.; BIAL Portela & Ca, S.A.; Mitsubishi Tanabe Pharma Corporation; and AbbVie Inc. The company was incorporated in 1992 and is headquartered in San Diego, California.

Regeneron Pharmaceuticals NASDAQ:REGN

$663.09 -1.43 (-0.22%)

Closing price 07/13/2026 04:00 PM Eastern

Extended Trading

$664.00 +0.91 (+0.14%)

As of 07/13/2026 07:59 PM Eastern

Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity. It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma; Praluent injection for heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in adults; REGEN-COV for covid-19; and Kevzara solution for treating rheumatoid arthritis in adults. In addition, the company offers Inmazeb injection for infection caused by Zaire ebolavirus; ARCALYST injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer; and develops product candidates for treating patients with eye, allergic and inflammatory, cardiovascular and metabolic, infectious, and rare diseases; and cancer, pain, and hematologic conditions. It has collaboration with Mammoth Biosciences, Inc. to research, develop and commercialize in vivo CRISPR-based gene editing therapies for multiple tissues and cell types. The company was incorporated in 1988 and is headquartered in Tarrytown, New York.

Vertex Pharmaceuticals NASDAQ:VRTX

$480.25 -5.14 (-1.06%)

Closing price 07/13/2026 04:00 PM Eastern

Extended Trading

$480.98 +0.73 (+0.15%)

As of 07/13/2026 07:59 PM Eastern

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor. The company's pipeline includes VX-522, a CFTR mRNA therapeutic designed to treat the underlying cause of CF, which is in Phase 1 clinical trial; VX-548, a non-opioid medicine for the treatment of acute and neuropathic pain which is in Phase 3 clinical trial; Exa-cel, for the treatment of sickle cell disease and transfusion-dependent beta thalassemia which is in Phase 2/3 clinical trial. In addition, it provides inaxaplin for the treatment of APOL1-mediated focal segmental glomerulosclerosis and co-morbidities, such as hypertension which is in single Phase 2/3; VX- 880 and VX-264, treatment for Type 1 Diabetes which is in Phase 1/2 clinical trial; VX-970, which is in Phase 2 clinical trial for the treatment of cancer; and VX-803 and VX-984 for treatment of cancer in Phase 1 clinical trial. Further, it sells the products to specialty pharmacy and specialty distributors in the United States, as well as retail pharmacies, hospitals, and clinics. Additionally, the company has collaborations with CRISPR Therapeutics AG.; Moderna, Inc.; Entrada Therapeutics, Inc.; Arbor Biotechnologies, Inc.; Mammoth Biosciences, Inc.; and Verve Therapeutics., as well as collaborations with Tevard Biosciences to develop novel tRNA-based therapies for duchenne muscular dystrophy. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest NBIX, MDY, CPRX, IMCR, AMGN, VRTX, REGN, and GILD Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest NBIX, MDY, CPRX, IMCR, AMGN, VRTX, REGN, and GILD Earnings

Compare Dividends

Latest NBIX, MDY, CPRX, IMCR, AMGN, VRTX, REGN, and GILD Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

NBIX, MDY, CPRX, IMCR, AMGN, VRTX, REGN, and GILD Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

NBIX, MDY, CPRX, IMCR, AMGN, VRTX, REGN, and GILD Company Descriptions

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools